Bio-Techne Corporation (TECH)
TECHNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$72.83
0.0000 (0.00%) today
Regular session, Nov 10, 9:35 AM ET
- Market cap
- $11.44bn
- P/E
- 42.3
- EPS, last 4 quarters
- $1.72
- Dividend yield
- 0.44%
- Day range
- $72.79 to $72.85
- 52-week range
- $43.20 to $72.88
- Average volume
- 2.90m
- Previous close
- $72.83
Analysts
4 coveringHold0 buy, 3 hold, 1 sell
Targets a year out average $73.00, +0.2% from here
Earnings
next estimate $0.4000Next report Nov 11, 2026
Sep 2025
0.0%
Dec 2025
+14.7%
Mar 2026
0.0%
Jun 2026
+6.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $295.88m | $311.42m | $321.19m | $299.71m |
| Gross profit | $191.28m | $208.29m | $211.39m | $196.62m |
| Operating income | $54.46m | $75.50m | $74.28m | $36.60m |
| Net income | $38.01m | $51.05m | $54.62m | $28.29m |
Last four quarters: revenue $1.23bn, margin 14.0%, free cash flow $308.20m
News
8 latest- Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue EstimatesZacks · 2 hours ago
- TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances Zacks · 1 day ago
- Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue EstimatesZacks · 1 day ago
- Bio-Techne Q1 Profit Down RTTNews · 1 day ago
- Bio-Techne Corporation Declares Quarterly Dividend of $0.08 Per ShareFintel · 6 days ago
- Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 3, 2026
- CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
- Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?Zacks · Nov 2, 2026
The company
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- bio-techne.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.